Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reported that the novel AKT inhibitor CCT128930 demonstrated significant antitumor activity in human cancer cell lines and xenografts, highlighting its potential as an anticancer therapy.

In this study, 12-Chloracetyl-PPD showed anti-cancer activity by inhibiting cancer cell viability and inducing apoptosis through reactive oxygen species production without harming normal cells.

This study found that doxorubicin-induced oxidative stress downregulates FLIPs and phosphorylates EF2, sensitizing prostate cancer cells to TRAIL; antioxidants may reduce doxorubicin's effectiveness, warranting further investigation.

This study observed that local injection of minoxidil effectively prevented Ara-C-induced alopecia in newborn rats, while topical application was ineffective.

In this study, the researchers observed that the severity of capecitabine-induced hand-foot syndrome in advanced gastric cancer patients was not linked to the IVS14+1G→A mutation in the DPYD gene.

The committee unanimously voted against recommending approval of the injectable cisplatin/epinephrine gel IntraDose for certain head and neck cancer patients, citing insufficient clinical benefit and concerns about toxicity in this study.

In this study, Cyanidin 3-O-arabinoside was found to protect against DHT-induced dermal papilla cell senescence and mitochondrial dysfunction in androgenetic alopecia, restoring hair growth in mouse models.

This study found that ALRN-6924 effectively protected human hair follicles from cyclophosphamide-induced damage in an ex vivo setting, suggesting it may reduce both acute and permanent chemotherapy-induced alopecia.

This study found that Danthron induced apoptosis in a human malignant melanoma cell line through mitochondrial, endoplasmic reticulum, and death receptor pathways.

This study found that increased Bcl-2 protein expression after DPCP treatment was associated with hair regrowth in alopecia areata patients, suggesting its role in inhibiting apoptosis.

This study found that the medication dyclonine has a potent inhibitory effect on the TRPV3 channel, effectively rescuing cell death and alleviating pruritus symptoms in a mouse model with gain-of-function TRPV3 mutations, suggesting potential for treating skin inflammation.

This study found that tetracycline can adhere to hair follicle structures and disrupt cell metabolism, potentially damaging healthy human cells as well as pathogens.

In this study using a mouse model, researchers found that DNA methylation of the miR-365-1 promoter plays a role in reducing apoptosis in hair follicle stem cells during chemotherapeutic alopecia.

This review details the preclinical and early clinical activity and side effects of docetaxel, showing its significant effectiveness against various cancers with neutropenia as a major side effect.

This study observed that a 24-hour pre-treatment with MitoQ significantly protected H9c2 myoblasts from doxorubicin-induced damage while enhancing doxorubicin's effectiveness in prostate cancer cells, outperforming dexrazoxane's effects without compromising the anti-cancer efficacy.

Vitamin D3 may prevent hair loss from chemotherapy, but side effects and cancer cell protection are concerns.

This case report found that a 48-year-old woman with idiopathic twenty-nail dystrophy experienced significant improvement in nail appearance after six months of treatment with oral Upadacitinib.

This study identified a heterozygous de novo mutation in the ODC1 gene causing a new disorder characterized by overgrowth and developmental delay, and suggests that DFMO treatment may help manage elevated ODC activity and putrescine levels.

In this study, in vitro and in vivo models showed that chrysin enhanced the efficacy of docetaxel and reduced its adverse effects in non–small cell lung cancer treatment.

This study screened synthesized pyridinecarboxamides for antitumor properties and found that many, particularly 5c and 7a, showed moderate in vitro activity against various human tumor cell lines.

In this study, a 68-year-old man with muscle-invasive bladder cancer and renal insufficiency achieved a partial radiological response to neoadjuvant therapy with gemcitabine and Disitamab Vedotin, without significant adverse events, highlighting a potential alternative for cisplatin-ineligible patients.

This study found that doxorubicin induces hair follicle apoptosis through TRAIL receptor signaling, providing insights for managing chemotherapy-induced hair loss.

In this mouse study, topical 1,25-dihydroxyvitamin D3 protected against cyclophosphamide-induced hair loss and inhibited mammary tumor growth, with effects varying by sex and tumor presence.

ATP-sensitive potassium channels are important for hair growth.

In this study, cyclic ADP-ribose (cADPR) treatment in human hair follicle dermal papilla cells was associated with increased intracellular calcium retention and activated anagen-related signaling without causing significant cytotoxicity, indicating its potential impact on hair growth processes.

In this pilot study, Doxil at 60 mg/m² every 4 weeks showed activity against hormone-refractory prostate cancer but was limited by severe mucocutaneous toxicities.

This phase I study determined that a combination of oral SU-014813 and docetaxel is a feasible treatment with a manageable safety profile and potential anti-tumor activity, particularly noted in melanoma and GIST patients.

This study found that doxorubicin disrupts hair-follicle-associated blood vessels, which may contribute to hair follicle dystrophy and alopecia in mice, but hair-follicle stem cells remained unaffected.

This study found that calcitriol protects keratinocytes from the cell detachment and apoptosis caused by captopril exposure.